Advanced search
Start date
Betweenand
Related content
(Reference retrieved automatically from Web of Science through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

Relationship of NAT2, CYP2E1 and GSTM1/GSTT1 polymorphisms with mild elevation of liver enzymes in Brazilian individuals under anti-tuberculosis drug therapy

Full text
Author(s):
Forestiero, Francisco Jose [1] ; Cecon, Leticia [1] ; Hirata, Mario Hirouki [1] ; de Melo, Fernando Fiuza [2] ; Cardoso, Rosilene Fressatti [3] ; Cerda, Alvaro [1] ; Crespo Hirata, Rosario Dominguez [1]
Total Authors: 7
Affiliation:
[1] Univ Sao Paulo, Dept Clin & Toxicol Anal, Sch Pharmaceut Sci, BR-05508000 Sao Paulo - Brazil
[2] Clemente Ferreira Inst, Sao Paulo - Brazil
[3] Univ Estadual Maringa, Dept Clin Anal & Biomed, Maringa, PR - Brazil
Total Affiliations: 3
Document type: Journal article
Source: Clinica Chimica Acta; v. 415, p. 215-219, JAN 16 2013.
Web of Science Citations: 8
Abstract

The relationship of NAT2, CYP2E1 and GSTM1/GSTT1 polymorphisms with mild elevation of liver biomarkers was investigated in individuals under anti-tuberculosis drug therapy. Tuberculosis outpatients (18-70 y) with (n = 59) and without (n = 40) mild increase of liver enzymes (MILE) at two-month treatment were selected. Blood samples were obtained for DNA extraction and evaluation of serum markers of liver function. NAT2, CYP2E1 and GSTM1/GSTT1 polymorphisms were detected by DNA sequencing, PCR-RFLP, and PCR multiplex. Frequency of NAT2{*}5/{*}5 genotype was higher in MILE than in non-MILE group (p = 0.04). Patients carrying NAT2{*}5/{*}5 genotype had increased susceptibility to MILE (OR: 9.00, 95CI: 1.46-55.48, p = 0.018). CYP2E1{*}5B allele ({*}1A/{*}5B plus {*}5B/{*}5B genotypes) carriers had a trend for reduced risk for MILE (OR: 0.34, 95CI: 0.11-1.03, p = 0.056) that was confirmed by lower levels of liver markers than CYP2E1{*}1A/{*}1A carriers after treatment (p < 0.05). Moreover, increased post-treatment ALT, AST and total bilirubin were associated with GSTM1{*}1/GSTT1{*}1 genotypes (p < 0.05). Patients taking CYP2E1 inhibitors had increased susceptibility to MILE (OR: 7.39, 95CI: 1.93-28.29, p = 0.003), which was independent of the studied polymorphisms. These results are suggestive that NAT2, CYP2E1 and GSTM1/GSTT1 polyrnorphisms and concomitant use of CYP2E1 inhibitors contribute to the susceptibility to mild alterations in liver enzymes in patients under anti-tuberculosis drug therapy. (c) 2012 Elsevier B.V. All rights reserved. (AU)